April 17 World Cancer Day
Over the past 20 years, great progress has been made in tumor diagnosis and treatment, from chemotherapy alone to targeted therapy, and then to immunotherapy in recent years, with an overall trend towards higher precision, efficacy and safety. Advances in diagnosis and treatment technology and successful R&D of innovative drugs have effectively prolonged the life cycle and improved the quality of life of patients. At the same time, anti-tumor treatment attaches more importance to whole-course management and psychological management, with an aim to improve patients' quality of life in an all-round way. The National Healthcare Security Administration has included a number of innovative drugs into the National Reimbursable Drug List one after another, further improving the accessibility of innovative drugs.
It has been the unswerving commitment of Hansoh Pharma over the past 20 years to keep continuous technological innovation to address the unmet clinical needs in anti-tumor treatment. As a leading R&D and manufacturing company of anti-tumor drugs in China, we uphold the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", focus on innovative R&D in the field of anti-tumor treatment, and have a series of innovative drugs on the market or in the pipeline, which brings better and more treatment options for patients, allows Chinese patients' access to good drugs, and lights up their hope for life and health.
Develop first generic drugs to break the monopoly and benefit millions of patients
At the beginning of the 21st century, the domestic anti-tumor treatment field was dominated by imported drugs, but the high cost of imported anti-tumor drugs brought a heavy economic burden to patients' families and the society. Since its establishment, Hansoh Pharma has been keeping its eyes on the world's advanced anti-tumor drugs, and has developed a series of first generic high-end anti-tumor drugs. We provide a number of high-quality drugs at more reasonable prices, such as Pulaile® (Pemetrexed Disodium for Injection), Zefei® (Gemcitabine Hydrochloride for Injection) and Xinwei® (Imatinib Mesylate Tablets), which greatly improves drug accessibility in related fields. We have been ranked number one in clinical usage of core varieties for successive years, and our anti-tumor product portfolio has served million of tumor patients and saved tens of billions of yuan in medical resources on a cumulative basis.
Pursue innovation and breakthrough to meet major clinical needs
Fore more than 20 years, Hansoh Pharma has been working in a concentrated, focused and professional manner, and pursuing innovation and breakthrough. It has kept high-intensity R&D investment, gathered scientific research talents, established R&D centers in Shanghai, Lianyungang, etc., and formed an efficient and leading R&D system. Up to now, Hansoh Pharma has made successive breakthroughs in major treatment fields and have successfully marketed four innovative drugs, two of which bring better choices for patients in the fields of NSCLC and CML.
Ameile® (Almonertinib Mesilate Tablets)
Ameile® (Almonertinib Mesilate Tablets) is China's first original third-generation EGFR-TKI innovative drug, and also the world's first third-generation EGFR-TKI with median progression-free survival (mPFS) exceeding one year (second-line use), intended for the treatment of "adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and are T790M mutation-positive". In terms of safety, the unique structural design of Ameile® reduces adverse reactions such as diarrhea and rash, which are common with existing EGFR-TKI, and no interstitial pneumonia occurred during the clinical study, which brings hope for long-term, high-quality survival to more patients with advanced NSCLC.
After Ameile® was approved for marketing, Hansoh Pharma is still actively exploring its therapeutic potential in the lung cancer segment, and has initiated a multi-project registered clinical study; in February 2021, the phase III study on first-line treatment of EGFR mutation-positive locally advanced or metastatic NSCLC reached the primary study endpoint.
Hansoh Xinfu® (Flumatinib Mesylate Tablets)
Hansoh Xinfu® (Flumatinib Mesylate Tablets) is China's first independently-developed "new second generation +" BCR-ABL tyrosine kinase inhibitor (TKI), intended for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in the chronic phase. Hansoh Xinfu® is "bi-directionally optimized" in terms of efficacy and safety, effectively reducing the rate of adverse events such as edema, limb pain, rash, etc., with better tolerability, and without other second-generation TKI-specific adverse events. The good safety meets the long-term treatment needs of patients, leading to not only prolonged survival but also improved quality of life of patients with CML. After Hansoh Xinfu® was approved for marketing, a real-world clinical study was conducted, and the data showed that Hansoh Xinfu® has remarkable therapeutic effect and better safety in real-world CML treatment, providing evidence basis for clinical medicine and a better treatment option for CML patients.
In December 2020, Ameile® and Hansoh Xinfu® were officially included in the National Reimbursable Drug List, which will help improve the accessibility and affordability of domestic innovative drugs as well as the standardization of clinical treatment, thus benefiting more patients and bringing more social benefits.
Provide whole-course management to improve patients' quality of life
With the iteration of drugs and the prolongation of survival of tumor patients, proper whole-course management of tumor patients, including vomiting and psychological management in chemotherapy, has become an important topic in oncology clinics.
In chemotherapy patients, nausea and vomiting are common adverse reactions, which seriously affect their quality of life. The best antiemetic regimen so far is a triple-drug regimen in which Fosaprepitant Dimeglumine for Injection must be used. Hansoh Pharma was the first to market Tanneng® (Fosaprepitant Dimeglumine for Injection) in China in 2019, filling the gap in the domestic market and greatly improving chemotherapy patients' compliance, quality of life and survival.
Tumor patients bear a great psychological burden, so it becomes increasingly important to manage their psychology well during treatment. As the largest manufacturer of central nervous system drugs in China, Hansoh Pharma's psychiatric products Oulanning® (Olanzapine Tablets) and Ameining® (Agomelatine Tablets) have good therapeutic effects on bipolar disorder and depression, which can help patients build up confidence and improve the effect of tumor treatment.
Create excellence in pharmaceuticals, enhance innovation in China
As a leading innovative pharmaceutical company in China, Hansoh Pharma has been ranked top three among China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline for successive years. In the future, Hansoh Pharma will continue to increase R&D investment, accelerate the pace of technological innovation, and keep moving forward through innovation and exploration on the road of improving patients' 5-year survival rate and 10-year survival rate, and even pursuing higher survival and ultimate cure of cancer. Protecting health with technology and lighting up hope with innovation, Hansoh Pharma will contribute more, newer and better innovative drugs to the society, and bring health and well-being to patients in China and even the world.